Skip to main content

Advertisement

SpringerLink
Log in

Role of the Medical Oncologist in the Management of Skin Cancer

  • Skin Cancer (JA Carucci, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Management of high-risk, recurrent, and metastatic skin cancers often requires a multi-modality, multi-disciplinary approach, with involvement of medical specialists in the fields of dermatology, surgical oncology, radiation oncology, and medical oncology. Medical oncologists typically treat skin cancers that have failed local therapies such as surgery or radiation and routinely manage metastatic skin cancers including melanoma, basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma. Here, we highlight the decision-making strategies employed by the medical oncologist in the management of high-risk and metastatic skin cancers and review the pertinent evidence for choice of systemic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Cancer Society. Cancer facts and figures 2014. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index. Accessed April 25, 2015.

  2. Eisemann N, Waldmann A, Geller AC, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Investig derm. 2014;134(1):43–50.

    Article  CAS  Google Scholar 

  3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.

    Article  PubMed  Google Scholar 

  4. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7.

    Article  PubMed  Google Scholar 

  5. Brougham ND, Dennett ER, Cameron R, Tan ST. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106(7):811–5.

    Article  PubMed  Google Scholar 

  6. Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options in Oncol. 2013;14(2):249–63.

    Article  Google Scholar 

  7. Society AC. What are the survival rates for melanoma skin cancer, by stage? http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-survival-rates. Accessed April 23, 2015.

  8. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29(4):241–52.

    Article  CAS  PubMed  Google Scholar 

  9. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. 2013;6, Cd008955.

    PubMed  Google Scholar 

  10. Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer (Oxford, England : 1990). 2012;48(2):218–25.

    Article  CAS  Google Scholar 

  11. Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011;12(2):144–52.

    Article  CAS  PubMed  Google Scholar 

  12. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(8):1614–21.

    CAS  Google Scholar 

  13. D. H. Lawson SJL, A. A. Tarhini, K. A. Margolin, M. S. Ernstoff, J. M. Kirkwood. E4679: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) vs placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(15s).

  14. Weiss SA, Chandra S, Pavlick AC. Update on vaccines for high-risk melanoma. Curr Treat Options in Oncol. 2014;15(2):269–80.

    Article  Google Scholar 

  15. Howard L Kaufman RHIA, Frances A. Collichio, Thomas Amatruda, Neil N. Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Yining Ye, Ai Li, Jennifer L. Gansert, Robert Coffin and Merrick I. Ross Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. Journal of Clinical Oncology. 2014;32(15 suppl (abstr 9008a)). Compares the T-VEC vaccine to GM-CSF for adjuvant therapy of melanoma and demonstrates potential impact of T-VEC on survival outcomes.

  16. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 2015 Mar 31 Investigates whether ipilimumab should be used in the adjuvant setting.

  17. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17. Highlights that anti-PD-1 immunotherapy may replace ipilimumab as choice of upfront single agent immunotherapy in advanced melanoma.

    Article  CAS  PubMed  Google Scholar 

  19. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33. Combination immunotherapy outperforms single agent ipilimumab in advanced melanoma.

    Article  CAS  PubMed  Google Scholar 

  20. Salama AK, Flaherty KT. BRAF in melanoma: current strategies and future directions. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(16):4326–34.

    Article  CAS  Google Scholar 

  21. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.

    Article  CAS  PubMed  Google Scholar 

  24. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.

    Article  CAS  PubMed  Google Scholar 

  25. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.

    Article  PubMed  Google Scholar 

  27. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014;16.

  28. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.

    Article  PubMed  Google Scholar 

  29. Atwood SX, Whitson RJ, Oro AE. Advanced treatment for basal cell carcinomas. Cold Spring Harbor Perspect Med. 2014;4(7):a013581.

    Article  Google Scholar 

  30. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma - molecular biology and potential new therapies. J Clin Invest. 2012;122(2):455–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012;118(21):5310–9.

    Article  CAS  PubMed  Google Scholar 

  32. Foley P. Current landscape for treatment of advanced basal cell carcinoma. Aust J Dermatol. 2015;56 Suppl 1:1–7.

    Article  Google Scholar 

  33. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol. 2011;50(6):645–58.

    Article  PubMed  Google Scholar 

  34. Hamid O, Goldenberg G. Identifying patients at risk for recurrent or advanced BCC. J Drugs Dermatol JDD. 2013;12(11):1246–52. quiz 53–4.

    PubMed  Google Scholar 

  35. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer (Oxford, England : 1990). 2014;50(4):774–83.

    Article  Google Scholar 

  36. Pazdur R. FDA Approval for vismodegib.

  37. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(8):2502–11.

    Article  CAS  Google Scholar 

  38. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  PubMed  Google Scholar 

  39. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9. Vismodegib has become a standard of care in advanced BCC.

    Article  CAS  PubMed  Google Scholar 

  40. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(7):1900–9.

    Article  CAS  Google Scholar 

  41. Migden M. Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(5):abstr 9009a.

  42. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):745–51.

    Article  CAS  Google Scholar 

  43. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer (Oxford, England : 1990). 1990;26(1):73–7.

    Article  CAS  Google Scholar 

  44. NCCN. NCCN guidelines squamous cell skin cancer. 2015.

  45. Parikh SA, Patel VA, Ratner D. Advances in the management of cutaneous squamous cell carcinoma. F1000 Prime Rep. 2014;6:70.

    Article  Google Scholar 

  46. Han A, Ratner D. What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion? Cancer. 2007;109(6):1053–9.

    Article  PubMed  Google Scholar 

  47. Brewster AM, Lee JJ, Clayman GL, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(15):1974–8.

    Article  CAS  Google Scholar 

  48. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.

    Article  CAS  PubMed  Google Scholar 

  49. Cooper JS, Zhang Q, Pajak TF, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–205.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030–2.

    Article  CAS  PubMed  Google Scholar 

  51. Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692–6.

    Article  CAS  PubMed  Google Scholar 

  52. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(25):3419–26.

    Article  CAS  Google Scholar 

  53. Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(5):1435–46.

    Article  CAS  Google Scholar 

  54. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37(1):20–7.

    Article  PubMed  Google Scholar 

  55. Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC, Gao L. Merkel cell carcinoma: epidemiology, target, and therapy. Curr Dermatol Rep. 2014;3:46–53.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science (New York, NY). 2008;319(5866):1096–100.

    Article  CAS  Google Scholar 

  57. Schrama D, Peitsch WK, Zapatka M, et al. Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Investig Dermatol. 2011;131(8):1631–8.

    Article  CAS  PubMed  Google Scholar 

  58. Sihto H, Kukko H, Koljonen V, Sankila R, Bohling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101(13):938–45.

    Article  CAS  PubMed  Google Scholar 

  59. Becker J, Mauch C, Kortmann RD, et al. Short German guidelines: Merkel cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2008 May;6 Suppl 1:S15-6.

  60. Schwartz JL, Griffith KA, Lowe L, et al. Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(8):1036–41.

    Article  Google Scholar 

  61. Fields RC, Busam KJ, Chou JF, et al. Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma. Cancer. 2012;118(13):3311–20.

    Article  PubMed  Google Scholar 

  62. Sundaresan P, Hruby G, Hamilton A, et al. Definitive radiotherapy or chemoradiotherapy in the treatment of Merkel cell carcinoma. Clin Oncol (Royal College of Radiologists (Great Britain)). 2012;24(9):e131–6.

    Article  CAS  Google Scholar 

  63. Poulsen M, Rischin D, Walpole E, et al. High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study--TROG 96:07. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(23):4371–6.

    Article  CAS  Google Scholar 

  64. Poulsen MG, Rischin D, Porter I, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006;64(1):114–9.

    Article  PubMed  Google Scholar 

  65. Chen MM, Roman SA, Sosa JA, Judson BL. The role of adjuvant therapy in the management of head and neck Merkel cell carcinoma: an analysis of 4815 patients. JAMA Otolaryngol-- head & Neck Surg. 2015;141(2):137–41.

    Article  Google Scholar 

  66. Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(12):2493–9.

    CAS  Google Scholar 

  67. Schlaak M, Podewski T, Von Bartenwerffer W, et al. Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma. Eur J Dermatol EJD. 2012;22(2):187–91.

    CAS  PubMed  Google Scholar 

  68. Davids MS, Charlton A, Ng SS, et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(26):e97–100.

    Article  Google Scholar 

  69. Cohen PR, Kurzrock R. Merkel cell carcinoma with a suppressor of fused (SUFU) mutation: case report and potential therapeutic implications. Dermatol Ther. 2015;15.

  70. Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther. 2010;6(3):382–4.

    Article  CAS  PubMed  Google Scholar 

  71. Lipson EJ, Vincent JG, Loyo M, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1(1):54–63.

    Article  CAS  PubMed  Google Scholar 

  72. NIH. ClinicalTrials.gov Merkel cell carcinoma. Accessed May 7, 2015.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Sarah A. Weiss, Melissa A. Wilson, and Anna C. Pavlick declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. New York University Perlmutter Cancer Center, 160 E. 34th St., 9th floor, New York, NY, 10016, USA

    Sarah A. Weiss, Melissa A. Wilson & Anna C. Pavlick

Authors
  1. Sarah A. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melissa A. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna C. Pavlick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna C. Pavlick.

Additional information

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weiss, S.A., Wilson, M.A. & Pavlick, A.C. Role of the Medical Oncologist in the Management of Skin Cancer. Curr Derm Rep 4, 205–212 (2015). https://doi.org/10.1007/s13671-015-0119-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-015-0119-0

Keywords

Search

Navigation